AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7880610
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving at least two cycles of rIL-2 by s.c. injections
Trial: 7880610
Drug: Development of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Development of anti-rIL-2 antibodies
Trial: 29396245
Drug: Azathioprine (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (100-200 mg per day for 48 weeks)
Trial: 20230389
Drug: Docetaxel reintroduction
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel reintroduction as second-line therapy
Trial: 9068935
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg/day titrated to 200 mg/day for 32 days
Trial: 8415898
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg, P.O.)
Trial: 27443570
Drug: Integrated orthogeriatric
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated orthogeriatric treatment
Trial: 23384428
Drug: Enzogenol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzogenol (1000 mg/day)
Trial: 9303253
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy group program for headaches; two 90-minute sessions focusing on relaxation, distraction, visualization, and stress management skills.
Trial: 9303253
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy group program for headaches; two 90-minute sessions.
Trial: 9303253
Drug: Follow-up ratings
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up ratings from parents after treatment.
Trial: 8314199
Drug: Semilente (amorphous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semilente (amorphous zinc insulin) injected at bedtime
Trial: 27094506
Drug: Standard-dose (SD)
RxNorm normalized name: Alphanine SD
DrugBank: Coagulation Factor IX Human (DB13152)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose (SD) group: 40 µg total vaccine dose, 20 µg at weeks 0 and 4
Trial: 27094506
Drug: High-dose dose-intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dose-intensive (HDDI) group: 80 µg total vaccine dose, 40 µg at weeks 0 and 4
Trial: 27094506
Drug: High-dose time-intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose time-intensive (HDTI) group: 80 µg total vaccine dose, 20 µg at weeks 0, 2, 4, and 6
Trial: 25058879
Drug: PDP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDP with ET‐Kyoto solution
Trial: 25058879
Drug: PDP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDP with cold storage/purification stock solution
Trial: 25058879
Drug: PDP groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDP groups (both solutions)
Trial: 21644
Drug: Melperone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone 100 mg X 3
Trial: 21644
Drug: Thiothixene 10
RxNorm normalized name: thiothixene 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiothixene 10 mg X 3
Trial: 1831016
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg IV)
Trial: 19559297
Drug: Lactobacillus rhammosus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhammosus GG (minimum dose, 10 degrees bacteria)
Trial: 16432349
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 500 mg intravenously before operation followed by 250 mg every 6 hours for 3 days
Trial: 15514192
Drug: Hydrochlorothiazide (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25 mg per day)
Trial: 15514192
Drug: Fosinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (20 mg per day)
Trial: 15514192
Drug: Hydrochlorothiazide plus
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide plus Pravastatin (40 mg per day)
Trial: 15514192
Drug: Fosinopril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril plus Pravastatin (40 mg per day)
Trial: 12748465
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine injection
Trial: 2663159
Drug: Ciclopirox olamine
RxNorm normalized name: Ciclopirox Olamine
DrugBank: Ciclopirox (DB01188)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclopirox olamine lotion 1%
Trial: 31216215
Drug: Ketorolac (10-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (10-mg tablets every 8 h)
Trial: 31216215
Drug: Gabapentin (300-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300-mg capsules every 8 h)
Trial: 26946615
Drug: Bloodletting therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bloodletting therapy at local myofascial trigger points and acupuncture at Jiaji (EX-B 2) points
Trial: 26946615
Drug: Lidocaine block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine block therapy
Trial: 17645494
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional intravenous treatment)
Trial: 15702859
Drug: L. plantarum
RxNorm normalized name: Lactobacillus acidophilus/L. plantarum/Bifido no.7 15 billion cell ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L. plantarum 299v in an oatmeal-fermented drink (10(9) CFU/ml) given twice daily
Trial: 11790498
Drug: 99mTc‐labelled lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐labelled lactose inhaled at four inspiratory flows (30, 40, 60, and 80 l/min)
Trial: 7573260
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg twice a day, slow-release capsules)
Trial: 2406228
Drug: Positive Radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Positive Radiation Group (PRG): further irradiation to a total dose of 90 Gy by the cone‐down and assault technique.
Trial: 6768079
Drug: Apomorphine (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (continuous IV infusion for 180-240 min)
Trial: 6768079
Drug: Post-infusion period
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-infusion period (240 min after apomorphine infusion)
Trial: 6768079
Drug: Haloperidol or
RxNorm normalized name: haloperidol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol or sulpiride (dopamine receptor blocking agents)
Trial: 24787908
Drug: Cholecalciferol (800,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (800,000 IU, 4000 IU daily)
Trial: 19857313
Drug: Antibiotics for
RxNorm normalized name: ANTIBIOTICS FOR TOPICAL USE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics for mild diverticulitis
Trial: 16351775
Drug: Ferrous fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate syrup (20 mg elemental Fe twice daily)
Trial: 12438475
Drug: Two weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two weeks of prednisolone 20 mg daily followed by two weeks of prednisolone 10 mg daily (n = 53)
Trial: 12438475
Drug: Two weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two weeks of prednisolone 20 mg daily and two weeks of placebo (n = 56)
Trial: 9389675
Drug: Urodilatin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Urodilatin infusion (40 ng / kg bw / min for 6 days)
Trial: 28170279
Drug: 74 g
RxNorm normalized name: WATER 99.9974 g in 100 L ORAL LIQUID [37.4]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 74 g raisins
Trial: 22287379
Drug: Point-of-care computed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point-of-care computed tomography (POC-CT) at the initial visit followed by medical therapy based on CT results (pre-CT group)
Trial: 22287379
Drug: Empiric medical
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric medical therapy (EMT) followed by POC posttreatment CT if symptoms persisted (EMT group)
Trial: 22287379
Drug: Empiric medical
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric medical therapy (EMT)
Trial: 22287379
Drug: Overall prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall prescriptions costs
Trial: 17880502
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 5% ALA solution
Trial: 17880502
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 10% ALA solution
Trial: 17880502
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 0.5%, 1%, 3%, 5%, or 10% ALA solution
Trial: 17880502
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of ALA solution
Trial: 9933475
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplementation (500 mg/day of elemental calcium and 700 IU/day of cholecalciferol)
Trial: 2196962
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg doxycycline
Trial: 7356102
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with 5‐fluorouracil, vinblastine, and cyclophosphamide
Trial: 29884572
Drug: Ethanol lock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanol lock therapy (70% ethanol)
Trial: 24000106
Drug: Weaning from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weaning from a convective incubator at 1,500 g body weight
Trial: 24000106
Drug: Weaning from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weaning from a convective incubator at 1,600 g body weight (control)
Trial: 24000106
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (1,500 g and 1,600 g)
Trial: 20506226
Drug: Intravenous autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous autologous ex vivo cultured MSCs (MSC group)
Trial: 20506226
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no MSC treatment)
Trial: 15820237
Drug: Bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion XL (up to 450 mg/day)
Trial: 29724865
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus administration of 400 µg TRH
Trial: 29724865
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL saline)
Trial: 27187893
Drug: Varenicline (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (active pill plus placebo patch)
Trial: 27187893
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch (active patch plus placebo pill)
Trial: 27187893
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo pill plus placebo patch)
Trial: 24756119
Drug: Multipurpose solution
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multipurpose solution
Trial: 17828765
Drug: 3-week control
RxNorm normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week control group instructed in writing about daily activities
Trial: 15668602
Drug: Fortified skimmed
RxNorm normalized name: Calcium fortified skimmed milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified skimmed milk containing 1,200 mg of calcium and 5.7 microg of vitamin D (group A)
Trial: 15668602
Drug: Fortified skimmed
RxNorm normalized name: Calcium fortified skimmed milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified skimmed milk containing 900 mg of calcium and 5.7 microg of vitamin D (group B)
Trial: 11881794
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 150 IU/kg or 300 IU/kg, administered 3 times weekly for 28 weeks
Trial: 7731768
Drug: iohexol 140
RxNorm normalized name: iohexol 140 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol 140 mgI/ml
Trial: 21189381
Drug: Intravenous calcium/magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous calcium/magnesium (1g calcium gluconate plus 1g magnesium sulfate pre‐ and post‐oxaliplatin)
Trial: 21189381
Drug: Intravenous calcium/magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous calcium/magnesium
Trial: 10940745
Drug: Daily prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily prednisone for 5 days during upper respiratory infection (URI)
Trial: 9737626
Drug: Ifetroban (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifetroban (250 mg daily)
Trial: 7920954
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ranitidine (0.15 mg/kg bolus followed by 0.15 mg/kg/hour for 12 hours)
Trial: 7920954
Drug: Bolus dosing
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dosing of ranitidine (1 mg/kg, two doses 6 hours apart)
Trial: 7920954
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (continuous infusion and bolus dosing)
Trial: 3401271
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bisacodyl solution
Trial: 3401271
Drug: Dulcolax Dragees
RxNorm normalized name: Dulcolax
DrugBank: Docusate (DB11089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulcolax Dragees (2 x 5 mg)
Trial: 3401271
Drug: Dulcolax suppository
RxNorm normalized name: bisacodyl Rectal Suppository [Dulcolax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulcolax suppository (10 mg)
Trial: 20470848
Drug: ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone 40 mg BID for 2 days, titrated up to 80 mg BID thereafter
Trial: 20470848
Drug: abrupt discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: abrupt discontinuation of conventional antipsychotics
Trial: 20470848
Drug: fast taper-50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fast taper-50% of conventional antipsychotic dosage on days 1 through 7, followed by discontinuation
Trial: 20470848
Drug: slow taper-100%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: slow taper-100% of conventional antipsychotic dosage on days 1 and 2, followed by 50% on days 3 through 7, then discontinuation
Trial: 18262432
Drug: Acetyl salicylic
RxNorm normalized name: Acetyl salicylic acid specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl salicylic acid (100 mg/die) and atorvastatin (10 mg/die) combined treatment
Trial: 16456725
Drug: Advice to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice to eat fatty fish or fish oil capsules (DART)
Trial: 16456725
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (DART 2)
Trial: 2628313
Drug: Oral prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prostaglandin E2 tablets (0.5-1.5 mg hourly)
Trial: 2628313
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (starting at 2 mU/min, max 64 mU/min)
Trial: 30286004
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (based on the combination of transverse diameter of cricoid ring and ED-LMB)
Trial: 30468986
Drug: Community-based cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based cohort (CC) participants
Trial: 30468986
Drug: Participants on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants on psychiatric treatment
Trial: 19925973
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic alone (40 mL)
Trial: 11464356
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic plus buprenorphine (0.3 mg)
Trial: 7809537
Drug: Itraconazole (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (6 mg/kg/day for 120 days)
Trial: 7809537
Drug: Allopurinol (8.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (8.5 mg/kg/day for 60 days)
Trial: 3422261
Drug: Short-term chemotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term chemotherapy with Adriamycin (ADR), cytarabine (ara-C), and thioguanine (TG) for 6 cycles
Trial: 3422261
Drug: Short-term chemotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term chemotherapy with Adriamycin (ADR), cytarabine (ara-C), and thioguanine (TG)
Trial: 28007348
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (conventional or sensor-augmented insulin pump therapy)
Trial: 28806095
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PRP injections)
Trial: 23456672
Drug: IM clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM clodronate 100 mg twice weekly (Group B)
Trial: 23456672
Drug: IM clodronate
RxNorm normalized name: Clodronic acid
DrugBank: Clodronic acid (DB00720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM clodronate 100 mg once weekly (Group A)
Trial: 20163263
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium patch
Trial: 16301721
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of water ingestion before ultrasonographic examination (Group A)
Trial: 16301721
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of water ingestion (Group A)
Trial: 9793190
Drug: GnRH analog
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH analog plus oral contraceptive (OC) therapy
Trial: 9793190
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) therapy alone
Trial: 7657122
Drug: Tamoxifen, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen, 20 mg/day per os (group A)
Trial: 2568711
Drug: alpha-agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-agonist
Trial: 2568711
Drug: pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pharmacological treatment
Trial: 364917
Drug: PGE2 gel
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PGE2 gel (1 mg in viscous gel)
Trial: 31279865
Drug: Aloysia polystachya
RxNorm normalized name: Aloysia citrodora flower oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloysia polystachya powdered leaves (300 mg, twice a day)
Trial: 16460294
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (20 mg for infants under 12 months, 40 mg for older children)
Trial: 10648454
Drug: Mesalamine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine (4 g daily for 18 months)
Trial: 10648454
Drug: Mesalamine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine (4 g daily for 18 months) in isolated small bowel disease subgroup